Group 1 - The company Sichuan Enwei Pharmaceutical Co., Ltd. has recently obtained a renewed Drug Production License from the drug regulatory authority [1] - The renewed license is valid until July 17, 2030, and covers various forms of medication including ointments, granules, tablets, and traditional Chinese medicine [1] - The company has authorized Hunan Taiyang Pharmaceutical Co., Ltd. to produce its exclusive product, Jiangnao Pain Relief Liniment, with a change in the classification code [1][2] Group 2 - The production of Jiangnao Pain Relief Liniment is expected to enhance the company's product structure, meet market demand, and positively impact revenue and profit metrics [2] - The product is indicated for the auxiliary treatment of local pain and swelling caused by rheumatic arthritis, showcasing its therapeutic benefits [2]

Core Viewpoint - Enwei Pharmaceutical's wholly-owned subsidiary, Sichuan Enwei Pharmaceutical Co., Ltd., has recently obtained a renewed Drug Production License, which is expected to positively impact the company's market product structure and financial performance [1][2]. Group 1: License Information - Sichuan Enwei has received a renewed Drug Production License valid until July 17, 2030, allowing the production of various forms of medication including ointments, granules, tablets, and capsules [1]. - The license number is 川20160226, and the company is located at 458, Section 3, Shuanghua Road, Shuangliu District, Chengdu, Sichuan Province [1]. Group 2: Product and Market Impact - The license change includes the authorization for Hunan Taiyang Pharmaceutical Co., Ltd. to produce the exclusive Chinese medicine product, Jiangnao Pain Relief Liniment, which is used for treating local pain and swelling caused by rheumatic arthritis [2]. - The production and market launch of Jiangnao Pain Relief Liniment are expected to optimize the company's product structure, meet market demand, and enhance revenue and profit metrics, contributing positively to the company's long-term operations [2].

Group 1 - The core point of the announcement is that Hunan Fangsheng Pharmaceutical Co., Ltd.'s subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., has received a Drug Production License from the Guangdong Provincial Drug Administration, allowing it to act as the marketing authorization holder for the drug Riluzole Tablets [1][2] - The Drug Production License is valid until January 26, 2031, and the production address is located in Changsha, Hunan Province, with the entrusted product being Riluzole Tablets [1] - The license is expected to help the company and its subsidiary integrate and allocate production and sales resources, improve capacity utilization, and reduce production costs [2] Group 2 - The short-term impact of obtaining the Drug Production License on the company's performance is not expected to be significant [2] - The pharmaceutical industry is characterized by uncertainties due to market conditions, industry policies, and supply-demand relationships, which can affect the production and sales of pharmaceutical products [2]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to hold the marketing authorization for RuLuGuoLi tablets [1] Group 1 - The Drug Production License enables the company and its subsidiary to integrate and allocate production and sales resources [1] - This development is expected to improve capacity utilization and reduce production costs [1] - The immediate impact on the company's financial performance is not expected to be significant [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410.HK) has received a Drug Manufacturing License from the Zhejiang Provincial Drug Administration, which is expected to positively impact the company's capacity expansion and market development in the long term [1]. Group 1: License Details - The company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is registered at 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang Province [1]. - The production address is entrusted to Kailaiying Life Science Technology (Tianjin) Co., Ltd., located at No. 71, Seventh Avenue, Tianjin Economic Development Zone [1]. - The license number is Zhe20260002, valid until January 22, 2031, issued by the Zhejiang Provincial Drug Administration [1]. Group 2: Implications of the License - The acquisition of the Drug Manufacturing License is anticipated to lay the foundation for the company to commence commercial production [1]. - This development is expected to provide better treatment options for patients, addressing urgent medical needs in cancer treatment [1].

Core Viewpoint - The company has recently obtained a "Drug Manufacturing License" from the Anhui Provincial Drug Administration, marking its first acquisition of such a license, which is expected to positively influence the company's long-term development [1] Group 1 - The acquisition of the "Drug Manufacturing License" will help optimize the company's product structure [1] - The company still needs to complete regulatory procedures, including product registration application, on-site verification, and compliance checks with GMP, before obtaining the "Drug Registration Certificate" for commercial production and sales [1] - The short-term impact of the "Drug Manufacturing License" on the company's operating performance is expected to be minimal [1]

Core Viewpoint - The company has received a renewed Drug Production License from the Hunan Provincial Drug Administration, ensuring its continued operations until November 6, 2030 [1]. Group 1: License Information - The new Drug Production License is valid until November 6, 2030, with the license number 湘20150132 [1]. - The company is authorized to produce a variety of pharmaceutical forms, including large volume injections, small volume injections, tablets, hard capsules, granules, syrups, tinctures, and traditional Chinese medicine preparations [1]. Group 2: Company Impact - The renewal of the Drug Production License is a routine procedure due to the expiration of the previous license, and it does not have a significant impact on the company's performance [1].

Core Viewpoint - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., has successfully obtained a renewed Drug Production License, ensuring its continued operations without significant impact on its business activities [1][2]. Group 1: License Details - The new Drug Production License is valid until August 7, 2030, replacing the previous license that was set to expire on November 5, 2025 [1]. - The company is located at No. 16, Xingguo Road, Xiuying District, Haikou City, with a social credit code of 9146000072122491XG [1]. - The license covers the production of small-volume injections, lyophilized powder injections, raw materials, and large-volume injections [1]. Group 2: Management and Oversight - The legal representative of the company is Wang Chengdong, with Li Jianming as the responsible person and Li Yuan as the quality manager [1]. - The daily supervision and management are conducted by the Hainan Provincial Drug Administration [1].